Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2008-04-08
2008-04-08
Bunner, Bridget E. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S350000, C530S387300, C536S023400
Reexamination Certificate
active
10954468
ABSTRACT:
A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
REFERENCES:
patent: 5164370 (1992-11-01), Ballard et al.
patent: 6329501 (2001-12-01), Smith
patent: 6509443 (2003-01-01), Dubaquie et al.
patent: 2002/0137023 (2002-09-01), Smith
patent: 2002/0164702 (2002-11-01), Valenzuela et al.
patent: WO 90/15142 (1990-12-01), None
patent: WO96/08274 (1996-03-01), None
patent: WO 97/21811 (1997-06-01), None
patent: WO98/50432 (1998-11-01), None
patent: WO98/53804 (1998-12-01), None
patent: WO 99/10494 (1999-03-01), None
patent: WO 03/070195 (2003-08-01), None
Heding et al., Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein 3, 1996, The Journal of Biological Chemistry, vol. 271, Issue 24, pp. 13948-13952.
Jansson et al., The insulin-like growth factor (IGF) binding protein 1 binding epitope on IGF-I probed by heteronuclear NMR spectroscopy and mutational analysis, 1998, The Journal of Biological Chemistry, vol. 273, No. 38, pp. 24701-24707.
Glass David J et al: Current Opinion in Neurpbiology, vol. 7, No. 3, 1997, pp. 379-384.
Glass D J et al: “Agrin acts via a musk receptor complex” CELL, May 17, 1996, vol. 85, No. 4, pp. 513-523.
Liyanage Yohan et al: Muscle and Nerve, vol. 25, No. 1, Jan. 2002, pp. 4-16.
Dubaquite et al: Biochemistry, vol. 38, May 18, 1998, pp. 6386-6396.
Shin S-U et al: Journal of Biological Chemistry, vol. 269, No. 7, Feb. 18, 1994, pp. 4979-4985.
Shin S-U et al: PNAS, vol. 87, No. 14, 1990, pp. 5322-5326.
Water et al. (1999) Angiostatin Binds to Smooth Muscle Cells in the Coronary Artery and Inhibits Smooth Muscle Cell Proliferation and Migration in Vitro. Arteriosclerosis Thrombosis and Vascular Biology 19:2041-2048.
Francis et al. (1995) CuZn Superoxide dismutase (SOD-1): Tetanus Toxin Fragment C Hybrid Protein for Targeted Delivery of SOD-1 to Neuronal Cells. J. Biol. Chem. 270:15434-15442.
Halin et al. (2002) Enhancement of the Antitumor Activity of interleukin-12 by Targeted Delivery to Neovasculature. Nature Biotechnology 20:264-269.
Ohno et al. (1995) Cell Targeting for Gene Delivery: Use of Fusion Protein Containing the Modified Human Receptor for Ecotropic Murine Leukemia Virus. Biochemical and Molecular Medicine 56:172-175.
Samoylova et al. (1998) Elucidation of Muscle-Binding Peptides by Phage Display Screen. Muscle and Nerve 22:460-466.
Donalies et al. (1991) Expression of M-Cadherin, a Member of the Cadherin Multigene Family, Correlates with Differentiation of Skeletal Muscle Cells. Proc. Natl. Acad. Sci. USA 88:8024-8028.
Chappuis-Flament et al. (2001) Multiple Cadherin Extracellular Repeats Mediate Homophilic Binding and Adhesion. J. Cell Bio. 154:231-243.
Leal, A.M.O., et al. (2002) Endocrinology vol. 143, No. 3, pp. 964-969.
Hill, J..J., et al., (2002) Jour. Of Biol. Chem., vol. 277, No. 43, pp. 40735-40741.
Wolfman, N.M., et al. (2003) PNAS, vol. 100, No. 26, pp. 15842-15846.
Kaufmann, U., et al. (1999) Journal of Cell Science, vol. 112, pp. 55-67.
Bunner Bridget E.
Dang Ian
Gregg, Esq. Valeta
Regeneron Pharmaceuticals Inc.
LandOfFree
Modified IGF1 polypeptides with increased stability and potency does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified IGF1 polypeptides with increased stability and potency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified IGF1 polypeptides with increased stability and potency will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3946176